Erika S. Berman Rosenzweig, MD
Director, Pulmonary Hypertension Center
Associate Professor of Clinical Pediatrics in Medicine

Columbia University Medical Center
New York, New York

Get Adobe Flash player Install latest flash player if you can't see this gallery.

Clinical Focus

  • Pediatric Cardiology 
Professional Education

BA:  University of Michigan, Ann Arbor, Michigan
Medical Degree:  Mount Sinai School of Medicine, New York, New York
Residency:   Pediatrics, New York- Presbyterian Hospital/ Columbia University Medical Center, New York, New York
Fellowship:  Pediatric Cardiology, New York- Presbyterian Hospital/ Columbia University Medical Center, New York, New York

Board Certification

Pediatric Cardiology

Clinical and Research Interests
  • Pulmonary Hypertension
  • Pulmonary arterial hypertension (adults and children)
  • Eisenmenger syndrome
  • Pulmonary hypertension associated with congenital diaphragmatic hernia
  • Clinical trials investigating novel therapies for the treatment of pulmonary hypertension in children and adults
  • Congenital heart disease
Dr. Erika Berman Rosenzweig is an Associate Professor of Clinical Pediatrics in Medicine. She has been a faculty member at Columbia University College of Physicians and Surgeons working in the Pulmonary Hypertension Center since 1999 and as the Director of The Pulmonary Hypertension Center since 2008.  She is trained as a pediatric cardiologist with expertise in congenital heart disease and has a joint appointment in the Department of Medicine caring for many adults and children with congenital structural heart disease and pulmonary vascular disease.

Dr. Rosenzweig completed her pediatric and pediatric cardiology training at Columbia University Medical Center where she has attended since. Clinical research in the area of novel drug development for the treatment of pulmonary hypertension have been a main focus of Dr. Rosenzweig’s academic career. She has authored over 50 publications including over 25 original manuscripts on topics related to pulmonary hypertension including Eisenmenger Syndrome. Dr. Rosenzweig frequently lectures at national and international meetings on these topics. She is also currently the Editor-in-Chief of the journal Advances in Pulmonary Hypertension.

Recent Publications

1: Bourge RC, Tapson VF, Safdar Z, Benza RL, Channick RN, Rosenzweig EB, Shapiro
S, White RJ, McSwain CS, Gotzkowsky SK, Nelsen AC, Rubin LJ. Rapid transition
from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial
hypertension. Cardiovasc Ther. 2013 Feb;31(1):38-44. doi:
10.1111/1755-5922.12008. PubMed PMID: 22970909; PubMed Central PMCID: PMC3561685.

2: Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD.
Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in
children with pulmonary arterial hypertension. Pediatr Pulmonol. 2013
Jan;48(1):27-34. doi: 10.1002/ppul.22555. Epub 2012 Apr 17. PubMed PMID:
22511577; PubMed Central PMCID: PMC3412194.

3: Abman SH, Kinsella JP, Rosenzweig EB, Krishnan U, Kulik T, Mullen M, Wessel
DL, Steinhorn R, Adatia I, Hanna B, Feinstein J, Fineman J, Raj U, Humpl T; On
behalf of the Pediatric Pulmonary Hypertension Network (PPHNet). Implications of
the FDA Warning Against the Use of Sildenafil for the Treatment of Pediatric
Pulmonary Hypertension. Am J Respir Crit Care Med. 2012 Dec 6. [Epub ahead of
print] PubMed PMID: 23220921.

4: Krishnan U, Takatsuki S, Ivy DD, Kerstein J, Calderbank M, Coleman E,
Rosenzweig EB. Effectiveness and safety of inhaled treprostinil for the treatment
of pulmonary arterial hypertension in children. Am J Cardiol. 2012 Dec
1;110(11):1704-9. doi: 10.1016/j.amjcard.2012.07.037. Epub 2012 Aug 21. PubMed
PMID: 22917554; PubMed Central PMCID: PMC3508003.